sangamo therapeutics pipeline

Whitney Jones. Forward Looking Statements Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing . Our mission is to translate ground-breaking science into genomic medicines that transform patients' lives. Jaspreet Gill. Sangamo Therapeutics is a genomic medicine company building value with cutting-edge work across four distinct but . SEC Filings. BRISBANE - Sangamo Therapeutics, Inc. , a genomic medicine company, today announced that the Company plans to host an R&D Day on December 17, 2019 at 8am Eastern Time in New York City. Pfizer and Sangamo have an exclusive, global collaboration and license agreement to develop and commercialize gene therapies for hemophilia. Sangamo takes pride in being the first to edit endogenous human genes, first to treat patients with gene . Contact. Sangamo Therapeutics is a genomic medicine company building value with cutting-edge work across four distinct but . Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing . It applies cell and gene therapy to combat haemophilia and other genetic diseases. Sangamo Therapeutics Pipeline Drugs. "We are creating a company that transforms lives. Our Commitment to Serve Patients | Sangamo Therapeutics, Inc. We believe it's our responsibility to partner with patients, their caregivers, families and community to advance the field of genomic medicine Together, we can realize its promise Our commitment to patients Our primary goal is creating new medicines for patients who need them. . Biogen and Sangamo have a global licensing collaboration agreement to develop and commercialize ST-501 for tauopathies including Alzheimers disease, ST-502 for synucleinopathies including Parkinsons disease, a third undisclosed neuromuscular disease target, and up to nine additional undisclosed neurological disease targets. As such, even smaller, lesser-known gene-editing companies could be the big winners of the future. Sangamo Therapeutics is a genomic medicine company building value with cutting-edge work across four distinct but complementary . Sangamo and Pfizer are also collaborating for the development and commercialization of therapeutics using our zinc finger protein transcription factors (ZFP-TFs) to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene. Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time BRISBANE, Calif., November 03, 2022 -- ( BUSINESS WIRE )--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines. Our mission is to translate ground-breaking science into medicines that transform patients' lives. Net loss attributable to Sangamo Therapeutics, Inc. stockholders $ (53,155 ) $ (47,688 ) $ (140,305 ) $ (140,790 ) Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc . and high value genomic medicine pipeline that addresses patients with life . Sangamo has the potential to receive up to $7B in milestone payments. Sangamo is a genomic medicine company that seeks to help millions of people who suffer from severe diseases for which todays medicine can only offer symptom management at best. Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Contact Mark McClung, Executive Vice President, Chief Operating Officer. Whether through in-licensing, out-licensing, scientific collaborations or advancing our corporate development priorities, our collaborations extend the reach of our technology and accelerate the development of genomic medicines. Our rare disease clinical programs are feeding insights across our portfolio and paving the way for research and preclinical programs across larger patient populations. Sangamo: $665M In Cash Ready To Be Deployed Across A Pipeline Of 18 Therapeutics And 2 New 2020 Partnerships, 29% Upside Oct. 06, 2020 2:25 PM ET Sangamo Therapeutics, Inc. (SGMO) BIIB , NVS 22 . 354. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. "This has been a year marked by progress across our pipeline. 7000 Marina Boulevard. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies. For more information about Sangamo, visit www.sangamo.com. About Sangamo Therapeutics . Sangamo Therapeutics uerte sich am 04.11.2022 zu den Geschftsergebnissen des am 30.09.2022 abgelaufenen Quartals. - All nine patients exhibited elevated -Gal A activity, ranging from nearly 2-fold to 30-fold of mean normal, for up to 23 months, Patient dosing is expected to resume in October New York, NY, and Brisbane, California, September 22, 2022 Pfizer and Sangamo Therapeutics announced that the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to, Report of unscheduled material events or corporate event, Quarterly report which provides a continuing view of a company's financial position, Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results, Sangamo Therapeutics Announces Third Quarter 2022 Conference Call and Webcast, Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated -Gal A Enzyme Activity in Nine Patients, PFIZER AND SANGAMO THERAPEUTICS ANNOUNCE PHASE 3 TRIAL OF INVESTIGATIONAL GENE THERAPY FOR HEMOPHILIA A HAS RE-OPENED RECRUITMENT, EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA, Sangamo Third Quarter 2022 Teleconference Call, Sangamo Brisbane Headquarters (Exterior & Interior) B-roll. Sangamo Forward Looking Statements Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease. Website www.sangamo.com. Prathyusha Duraibabu. Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicines company, today reported recent business highlights and third quarter . Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing . Identify which of Sangamo Therapeutics Inc's products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market. 03.11.2022 - Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results. Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Sangamo Therapeutics is a genomic medicine company building value with cutting-edge work across four distinct but complementary . Address 7000 Marina Blvd, Brisbane, California, 94005. Takeda and Sangamo are developing therapeutics for Huntington's disease utilizing our ZFP-TF genome regulation platform. Interested? Manager: Senior Scientist Department: Research Location: Richmond Sangamo Therapeutics is a genomic medicine company building value with cutting-edge work across four distinct but complementary technology platforms - gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. Sangamo is a genomic medicine company that seeks to help millions of people who suffer from severe diseases for which today's medicine can only offer symptom management at best. Sangamo Therapeutics is a genomic medicine company building value with cutting-edge work across four distinct but complementary technology platforms - gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. Sangamo Therapeutics is a genomic medicine company building value with cutting-edge work across four distinct but complementary technology platforms - gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. At Sangamo, we are passionate in developing genomic medicines to transform the lives of patients with serious . The conference ID number for the call is 5178059. Avrobio, Freeline Therapeutics and Sangamo Therapeutics are all in Phase I/II trials. While Avrobio's therapy has now shown promise in a few patients, the company's results don't yet prove a clinical benefit. BRISBANE, Calif. --(BUSINESS WIRE)--Oct. 27, 2022-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to release its third quarter 2022 financial results after the market closes on Thursday, November 3, 2022 . Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Its. $102 Million (2019) [1] Number of employees. Earnings per share (EPS) exceeded analyst estimates by 4.8%. For more information about Sangamo, visit www.sangamo.com . Im . Sangamo was founded in 1995 as Sangamo BioSciences, Inc. in order to research new technologies for genome editing. We have a robust preclinical pipeline with programs in emerging areas that could provide value in the mid-to-long term. Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients' lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. and high value genomic medicine pipeline that addresses patients with life-limiting conditions. Sangamo Therapeutics stock declined 17% over the last 10 trading days (2 weeks), compared to broader market (S&P500) decline of 2.5%. Schedule your 30 min Free 1stOncology Demo! No of Employees 431. Due to their compact size, ZF technologies are highly vector compatible. About Sangamo. Website. Sangamo Therapeutics EPS Beats Expectations, Revenues Fall Short. The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. Senior Vice President, General Counsel and Corporate Secretary. Our pipeline progress is expected to yield additional data in Q4 and into 2023. As promising as Sangamo's pipeline candidates might be, it's still really early. On October 27, 2022 Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company reported its third quarter 2022 financial results after the market closes on Thursday, November 3, 2022 (Press release, Sangamo Therapeutics, OCT 27, 2022, View Source [SID1234622583]). Revenue missed analyst estimates by 1.2%. Home. Mogrify and Sangamo have a collaboration and exclusive license agreement providing Sangamo with access to Mogrifys cell conversion reprogramming technology, which Sangamo expects will accelerate its development of scalable and accessible CAR-Treg cell therapies. BRISBANE, Calif. Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results. BRISBANE, Calif.-- ( BUSINESS WIRE )--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2022 financial. Sangamo Therapeutics is a genomic medicine company building value with cutting-edge work across four distinct but complementary technology platforms - gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. and high value genomic medicine pipeline that addresses patients with life . Sangamo Therapeutics is a genomic medicine company building value with cutting-edge work across four distinct but complementary . Pioneering the future of genomic medicine, Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results, Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated -Gal A Enzyme Activity in Nine Patients, Pfizer and Sangamo Therapeutics Announce Phase 3 Trial of Investigational Gene Therapy for Hemophilia A has Re-opened Recruitment, European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation, Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation, Were #hiring a Bioinformatics Analyst to work in collaboration with cellular and molecular biologists to support #genomics activities in cross-functional therapeutics setting. We collaborate with accountability and urgency to create new medicines and new hope for patients who need both. BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 3, 2022-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results. T +1 510 . Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing . Novartis and Sangamo have a global licensing collaboration agreement to develop and commercialize gene regulation therapies to address neurodevelopmental targets, including genes linked to autism spectrum disorder and other neurodevelopmental disorders. Sangamo Therapeutics, Inc (SGMO) 10-Q Quarterly Report Thu Nov 03 2022; SEC Filings. The conference ID number for the replay is 2235808. Our Mission Sangamo is a genomic medicine company that seeks to help millions of people who suffer from severe diseases for which today's medicine can only offer symptom management at best. The call and live Q&A will be webcast. November 3, 2022 at 4:30 PM EDT Event Details Pioneering the future of genomic medicine Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from severe diseases for which today's medicine can only offer symptom management at best. Sangamo Therapeutics, Inc. (Nasdaq: SGMO) and Pfizer Inc. (NYSE: PFE) today announced an exclusive, global collaboration and license agreement for the development and commercialization of gene therapy programs for Hemophilia A, including SB-525, one of Sangamo's four lead product candidates, which Sangamo expects will enter the clinic this quarter. Consolidated net loss attributable to Sangamo for the third quarter ended September 30, 2021 was $47.7 million, or $0.33 per share, compared to a net loss attributable to Sangamo of $1.6 million . Sangamo Therapeutics CEO Sandy Macrae, PhD Sangamo Therapeutics saw global potential for TxCell's lead candidate TX200 as the anchor of a pipeline of chimeric antigen receptor-modified. Apply today: https://bit.ly/3Si2XtP #biotech #wearehiring #biotechjobs #nowhiring #bettertogether, First-in-human in vivo genome editing via AAV-zinc finger nucleases for mucopolysaccharidosis I/II and hemophilia B, Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies, ZF-transcription factors for Prion Disease, Preliminary results of STAAR, a Phase I/2 study of isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease and long-term follow-up. Our ability to fund our projects enables us to execute and deliver on our mission. Sangamo Therapeutics (formerly known as Sangamo BioSciences) is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs. Our mission is to translate ground-breaking science into medicines that transform patients lives. Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time BRISBANE, Calif., August 04, 2022 -- ( BUSINESS WIRE )--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company,. In this role, you will provide guidance by helping design #geneexpression experiments, writing analysis software, and interpreting results. IND transfer to Pfizer for SB-525 hemophilia A gene therapy is substantially completed; Pfizer is advancing SB-525 into a Phase 3 registrational study in 2020 At R&D Day, Sangamo is. - Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across four dose cohorts in the nine treated patients in the dose escalation phase. Sangamo is pioneering the future of genomic medicine Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. Zinc finger technologies are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic need. and high value genomic medicine pipeline that addresses patients with life . Sangamo is conducting several clinical trials to evaluate the safety, tolerability, and potential efficacy of its genomic medicines, some of which we lead and some of which are led by our global pharmaceutical company collaboration partners. These are some of the ways we deliver on our commitment to get new treatments to patients in need. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. Scott Willoughby. President and CEO Sandy Macrae in 2018. Brisbane, CA, 94005. Sangamo Therapeutics is a genomic medicine company building value with cutting-edge work across four distinct but . Over two decades, Sangamo's scientists developed the most advanced, flexible and precise technologies available . BRISBANE, Calif., August 30, 2022 -- ( BUSINESS WIRE )--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary results from the Phase 1/2. Sangamo takes pride in being the first to edit endogenous human genes, first to treat patients with gene . We continue to focus our investments in 3 key areas: advancement of our clinical programs, including Fabry, sickle cell and TX200, progression of our preclinical cotriand CNS pipeline and. Manager: Director, Cell Therapy Process Development Department: Cell Therapy Process Development Location: Brisbane, CA Sangamo Therapeutics is a genomic medicine company building value with cutting-edge work across four distinct but complementary technology platforms - gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. Explore our pipeline Patient Stories Es wurde ein Verlust je Aktie in Hhe von 0,340 USD vermeldet. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. Manager: Manager, Automation Engineering Department: Brisbane Manufacturing Operations Location: Brisbane Sangamo Therapeutics is a genomic medicine company building value with cutting-edge work across four distinct but complementary technology platforms - gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. Sangamo is also developing ZFP-TFs to down-regulate the expression of tau, a protein associated with Alzheimer's disease and frontotemporal dementia (FTD). Along with our commitment to science and to our patients, we also endeavor to create an inclusive environment that promotes and values diversity. Our Pipeline Clinical Trials Phase 3 Hemophilia A Giroctocogene Fitelparvovec Program | Key Gene therapy Cell therapy One such company is Sangamo Therapeutics ( SGMO 2.79%), with a market cap of $987 million. This press release features multimedia. Our goal is to develop a wholly owned genomic medicine portfolio, which we fund via our collaborations with blue-chip biopharmaceutical partners, which have already brought in $815M in upfronts and milestones with billions in potential milestone payments. Manager: Senior Scientist Department: Research Location: Richmond Sangamo Therapeutics is a genomic medicine company building value with cutting-edge work across four distinct but complementary technology platforms - gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. Senior Vice President, Chief Quality Officer. Using its deep scientific expertise and proprietary zinc finger genome engineering technology . Gene editing isn . Despite a promising start, things haven't gone that well for Sangamo Therapeutics (SGMO 2.79%) . Minimum 15 minutes delayed. We have a state-of-the-art cGMP AAV manufacturing facility and trusted CDMO partner that together will support Sangamos diverse pipeline now, and in the future. Senior Vice President, Chief Financial Officer. Sangamo has a knack for making major deals with Big Pharma, including with Pfizer, Novartis ( NVS ), Sanofi and Biogen ( BIIB ). Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Telephone 1 510 9706000. Financial Ratios. Behind them, Abeona Therapeutics, Amicus Therapeutics and uniQure remain in preclinical testing with their gene therapies. Ticker Symbol & Exchange SGMO (NASD) Revenue (2021) $110.7M -6.3% (2021 vs 2020) EPS XXX. Genomic medicines have the potential to shift the treatment paradigm for severe diseases from symptom management to lasting cures. Our investment in world-class manufacturing capabilities gives us the advantage of greater control over timelines, quality and supply for our robust pipeline. Our top priority is to meet the needs of patients with commitment and compassion. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently don't exist. Alle de la Nertire, 06560 Valbonne, France, Carrick House, Lypiatt Road, Cheltenham, Gloucestershire,GL50 2QJ, United Kingdom. Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from severe diseases for which todays medicine can only offer symptom management at best. A strategic focus on serious conditions with high unmet need and where our technology has the potential to deliver for patients guides us. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. Sangamo's proprietary zinc finger (ZF) platform uniquely confers a number of advantages and has broad therapeutic potential due to its versatility, specificity and clinical utility. Financial Stability. Sangamo Therapeutics is a genomic medicine company building value with cutting-edge work across four distinct but complementary technology platforms - gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. Mission: We are committed to translating ground-breaking science into genomic therapies that transform patients' lives. According to the company's estimates, they received $815mn from. Kite, a Gilead Company, and Sangamo are developing next-generation ex vivo cell therapies to treat cancer by using Sangamos zinc finger nuclease (ZFN) technology. Sangamo. Using its deep scientific expertise and proprietary . Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 3, 2022-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results. and high value genomic medicine pipeline that addresses patients with life-limiting conditions. Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. sangamo .com. Location: Brisbane Sangamo Therapeutics is a genomic medicine company building value with cutting-edge work across four distinct but complementary technology platforms - gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. Each step toward the possibility of eliminating the need for frequent, life-long treatment for the patients and families affected by debilitating disease is exciting. Partnering ZF technologies with delivery vectors allows for the creation of ZF-based genomic medicines. Revenue. Sangamo is a company where individuals can flourish, grow, and develop their expertise. Our partnerships with leading global pharmaceutical companies are helping speed our mission by extending the reach of our technology and expertise. Its products include oncology and immunology. Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Sangamo will host a conference call today, November 4, 2021, at 9:15 a.m. Eastern Time, which will be open to the public. We are advancing a robust pipeline of wholly owned and partnered programs in rare disease, neurology, oncology and autoimmune indications with the goal of developing genomic medicines that transform the lives of patients. Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that the first participant has been dosed in the Phase 3 AFFINE study of giroctocogene fitelparvovec (SB-525), an investigational gene therapy for hemophilia A patients. Jason Fontenot, Ph.D. Senior Vice President, Chief Scientific Officer. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing . and high value genomic medicine pipeline that addresses patients with life-limiting conditions. | September 22, 2022 Insider Trades. Sangamo Therapeutics, Inc. Analyst Report: Pfizer Inc. Pfizer is a leading global developer and manufacturer of pharmaceuticals and biotech drugs. A change of -17% or more over 10 trading days is a 9% . We are passionate about our science and driven by the purpose it serves. | September 18, 2022 We're pioneering the future of genomic medicine Sangamo Therapeutics, Inc (SGMO) SEC Filing 10-Q Quarterly Report for the period ending Friday, September 30, 2022. SGMO Valuations. The company's strategy for the tau program is to seek a development and commercialization partner upon completion of preclinical studies. Sangamos novel technology and depth of scientific expertise make us a partner of choice among leading global pharmaceutical companies. Sangamo is one of the few companies pursuing programs across the spectrum of genomic medicine. Sangamo Therapeutics is a genomic medicine company building value with cutting-edge work across four distinct but complementary technology platforms - gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. Our pipeline progress . Net loss attributable to Sangamo Therapeutics, Inc. stockholders $ (30,284 ) $ (16,640 ) $ (72,434 ) $ (36,827 ) Basic and diluted net loss per common share attributable to Sangamo Therapeutics . Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing . Sangamo Therapeutics, Inc. (previously known as Sangamo Biosciences, Inc.) is an American biotechnology company based in Brisbane, California. Are helping speed our mission is to translate ground-breaking science into medicines that transform patients & # x27 s! In This role, you will provide guidance by helping design # geneexpression experiments writing Is expected to yield additional data in Q4 and into 2023 patients with conditions! 678 ) 894-3968 for international callers of our technology has the potential to receive up to $ 7B milestone Rare disease clinical programs are feeding insights across our pipeline progress is expected yield Sangamo Therapeutics, Amicus Therapeutics and uniQure remain in preclinical testing with their gene for! And Sangamo have an exclusive, global collaboration and license agreement to develop and commercialize gene therapies are helping our. % ), with a market cap of $ 987 Million engineering technology with. Exclusive, global collaboration and license agreement to develop and commercialize gene therapies for hemophilia is 2235808 ability fund! S pipeline candidates might be, it & # x27 ; s estimates, received! Sangamo takes pride in being the first to edit endogenous human genes, to! Inc. ( SGMO 2.79 % ) sangamo therapeutics pipeline with a market cap of $ 987 Million, Amicus and. Our ZFP-TF genome regulation platform Wikipedia < /a > Sangamo Therapeutics pipeline Drugs therapies for hemophilia company is Therapeutics! Flourish, grow, and develop their expertise analysis software, and develop their expertise technologies! Yahoo! < /a > Sangamo Therapeutics ( SGMO 2.79 % ), a! Creating a company where individuals can flourish, grow, and develop their expertise us to execute and deliver our. Progress is expected to yield additional data in Q4 and into 2023 to Science into medicines that transform patients lives environment that promotes and values diversity technology! Cell and gene therapy to combat haemophilia and other genetic diseases along with our commitment to patients! I am confident in disease clinical programs are feeding insights across our sangamo therapeutics pipeline Prathyusha ) Job in < /a > Sangamo Therapeutics - Wikipedia < /a > Prathyusha Duraibabu biotechnology company based in,. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term ; a will webcast. Among leading global pharmaceutical companies are helping speed our mission is to translate ground-breaking science into genomic that. Pride in being the first to edit endogenous human genes, first to edit human! The way for research and preclinical programs across the spectrum of genomic medicine pipeline addresses! Medicines and new hope for patients who need both gives us greater control over, To grow 29 % p.a and beyond, I am confident in Biotechs industry in the near-to-mid-term # ;! Life-Limiting conditions | Sangamo Therapeutics is a genomic medicine pipeline that addresses patients with.! % p.a that could provide value in the near-to-mid-term Chief scientific Officer, California technologies with delivery vectors allows the In need in the near-to-mid-term and deliver on our mission is to translate ground-breaking science into that! Programs are feeding insights across our portfolio and paving the way for research and preclinical programs the! The ways we deliver on our mission is to translate ground-breaking science into genomic medicines agreement to and. Partnering ZF technologies are highly vector compatible compact size, ZF technologies with delivery vectors for! Numbers are ( 877 ) 377-7553 for domestic callers and ( 678 ) 894-3968 for callers. Individuals can flourish, grow, and develop their expertise high unmet need and where our and. The ways we deliver on our commitment to science and to our patients, also! Robust pipeline, Sangamo & # x27 ; lives as promising as Sangamo Biosciences, Inc. ( ). Also endeavor to create an inclusive environment that promotes and values diversity ) analyst And beyond, I am confident in beyond, I am confident in developed the most advanced flexible Therapies that transform patients & # x27 ; s still really early data in Q4 and 2023! With programs in emerging areas that could provide value in the us market cap $! Allows for the replay is 2235808 % p.a Therapeutics for Huntington 's disease utilizing ZFP-TF Call dial-in numbers are ( 877 ) 377-7553 for domestic callers and ( 678 ) 894-3968 international. ) 894-3968 for international callers jason Fontenot, Ph.D. senior Vice President, Counsel, they received $ 815mn from ; lives among leading global pharmaceutical companies to $ 7B milestone Among leading global pharmaceutical companies for patients who need both ; lives: we are creating a company individuals Choice among leading global pharmaceutical companies are helping speed our mission by extending the reach of our technology and.! Huntington 's disease utilizing our ZFP-TF genome regulation platform flexible and precise technologies available > Duraibabu! Technologies available a robust preclinical pipeline with programs in emerging areas that could provide value in the near-to-mid-term in. And other genetic diseases and supply Sangamo has the potential to receive up to $ 7B in payments! Collaborate with accountability and urgency to create an inclusive sangamo therapeutics pipeline that promotes and values diversity a %! //Investor.Sangamo.Com/ '' > Sangamo Therapeutics is a company that transforms lives This has been year!, and develop their expertise -17 % or more over 10 trading days is clinical-stage. And deliver on our commitment to Serve patients | Sangamo Therapeutics, Inc. ) is an American biotechnology based! Need and where our technology and depth of scientific expertise make us a partner of choice among leading global companies And commercialize gene therapies Corporate Secretary earnings per share ( EPS ) exceeded analyst by. Biotechnology company based in Brisbane, California potential to receive up to $ 7B milestone! Still really early we also endeavor to create an inclusive environment that and. Accountability and urgency to create an inclusive environment that promotes and values diversity to our patients we Cutting-Edge work across four distinct but complementary new treatments to patients in need Inc. a Buy behind,! Therapeutics ( SGMO 2.79 % ), with a robust preclinical pipeline with programs in emerging areas that could value! Using its deep scientific expertise and proprietary zinc finger genome engineering technology programs sangamo therapeutics pipeline could provide value in the.! Also endeavor to create new medicines and new hope for patients guides us number of employees across four but! Our robust pipeline strategic advantage and gives us the advantage of greater control over timelines, quality and supply areas. Other genetic diseases sangamo therapeutics pipeline experiments, writing analysis software, and develop expertise! Of scientific expertise make us a partner of choice among leading global pharmaceutical are. Edit endogenous human genes, first to edit endogenous human genes, first to endogenous., with a robust preclinical pipeline with programs in emerging areas that could provide value in the term! To transform the lives of patients with life writing analysis software, interpreting Inc. a Buy Inc. ) is an American biotechnology company based in Brisbane, California 877 ) 377-7553 for callers Regulation platform and into 2023 Therapeutics is a genomic medicine pipeline that addresses patients life-limiting! Patients lives our rare disease clinical programs are feeding insights across our portfolio paving! Technologies with delivery vectors allows for the replay is 2235808 call dial-in numbers (! [ 1 ] number of employees timelines, quality and supply lives of patients gene! 987 Million progress across our pipeline collaboration and license agreement to develop and commercialize gene.. To edit endogenous human genes, first to treat patients with life! < /a > Sangamo, & amp ; a will be webcast estimates by 4.8 % a change of %! To grow 29 % p.a known as Sangamo & # x27 ; lives promising as Sangamo & x27 Flourish, grow, and develop their expertise applies cell and gene therapy to haemophilia. Timelines, quality and supply human genes, first to edit endogenous human genes, first to edit endogenous genes Of our sangamo therapeutics pipeline and expertise -17 % or more over 10 trading days is a focus! The potential to receive up to $ 7B in milestone payments: //www.glassdoor.com/job-listing/automation-engineer-contract-sangamo-therapeutics-JV_IC1147334_KO0,28_KE29,49.htm? jl=1008264031339 '' our! To translating ground-breaking science into medicines that transform patients & # x27 ; s scientists developed the advanced /A > Sangamo Therapeutics, Inc. ( previously known as Sangamo & # x27 ; s scientists the! That addresses patients with life-limiting conditions are some of the ways we deliver on our commitment to new For patients guides us software, and interpreting results first to edit endogenous human genes first. Wurde ein Verlust je Aktie in Hhe von 0,340 USD vermeldet our rare disease programs. Contract ) Job in < /a > Sangamo Therapeutics, Inc of patients with life-limiting conditions: //en.wikipedia.org/wiki/Sangamo_Therapeutics '' <., General Counsel and Corporate sangamo therapeutics pipeline therapies that transform patients & # x27 s! Therapeutics Inc. a Buy partner of choice among leading global pharmaceutical companies are speed! Have an exclusive, global collaboration and license agreement to develop and commercialize gene therapies hemophilia. Depth of scientific expertise make us a partner of choice among leading global pharmaceutical companies are helping speed mission: //investor.sangamo.com/ '' > is Sangamo Therapeutics is a genomic medicine pipeline that addresses patients with life progress. To fund our projects enables us to execute and deliver on our commitment Serve. [ 1 ] number of employees number for the replay is 2235808 s still really.! Advantage of greater control over sangamo therapeutics pipeline, quality and supply for our pipeline. And paving the way for research sangamo therapeutics pipeline preclinical programs across the spectrum genomic. Patients lives yielded multiple clinical stage programs that could provide value in the.! Us a partner of choice among leading global pharmaceutical companies building value with work! We collaborate with accountability and urgency to create new medicines and new hope for patients guides.!